Journal
CURRENT DRUG TARGETS
Volume 12, Issue 14, Pages 2079-2090Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138945011798829357
Keywords
Apoptosis; cancer; DR4; DR5; DcR1; DcR2; TRAIL and clinical trials
Categories
Funding
- AT&T Endowed Chair at The Institute for Drug Development
- Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio
- Dutch Cancer Society [RUG 2005-3361, RUG 2005-3365, VU 2006-3567]
- EU [LSHC-CT-2006-037686]
- TI Pharma [T3.112]
Ask authors/readers for more resources
Tumor necrosis factor-related apoptosis-inducing ligand or Apo2 ligand (TRAIL/Apo2L) is a member of the tumor necrosis factor (TNF) superfamily that induces apoptosis upon binding to its death domain-containing transmembrane receptors. The preferential toxicity of TRAIL to cancer cells and the sparing of normal cells make it an ideal cancer therapeutic agent. TRAIL induces apoptosis via the extrinsic death receptor apoptotic pathway and activates the JNK, ERK, Akt and NF-kappa B signaling cascades. However, not all cancer cells are sensitive to TRAIL therapy. This may limit its efficacy in the clinic, although ways have already been identified to overcome resistance by combining TRAIL with chemotherapeutic and other biological agents. This review focuses on TRAIL receptor-targeting as anticancer therapy, the apoptotic signaling pathways induced by TRAIL receptors, the prognostic implications of TRAIL receptor expression and modulation by combination therapies. The mechanisms of TRAIL resistance and strategies to overcome drug resistance will also be addressed. Finally, the progress of TRAIL and DR4/DR5-specific agonistic antibodies in clinical trials and the development of new receptor-selective TRAIL variants are discussed including future directions for apoptosis inducing therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available